Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

565
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
565
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.7K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.7K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.3K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.3K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

555
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
555
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

959
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
959
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

837
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
837

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Inflammatory bowel disease in the aging population.

Inflammatory bowel diseases·2026
Same author

Multi-task artificial intelligence annotation of echocardiographic images: a retrospective multi-cohort study.

medRxiv : the preprint server for health sciences·2026
Same author

Dual-targeted therapy with risankizumab and upadacitinib in medically complex Crohn's disease.

Crohn's & colitis 360·2026
Same author

Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients with Baseline Cardiovascular Risk.

The American journal of gastroenterology·2026
Same author

Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease.

Digestive diseases and sciences·2026
Same author

Primer: Understanding Medicare for Advanced Therapies for Inflammatory Bowel Disease.

The American journal of gastroenterology·2026

Video Experimental Relacionado

Updated: Feb 24, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.7K

Combinación curcumina-QingDai para la colitis ulcerosa activa: un análisis de costo-efectividad.

Henit Yanai1, David Choi2, Shomron Ben-Horin3

  • 1Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
|February 22, 2026
PubMed
Resumen

La curcumina y QingDai (CurQD) ofrece un tratamiento rentable para la colitis ulcerosa (UC) en comparación con las terapias avanzadas. Este nutracéutico proporciona beneficios significativos, por lo que es una opción valiosa para los pacientes con UC activa.

Palabras clave:
rentabilidad costo-eficacia.enfermedad inflamatoria del intestino enfermedad inflamatoria del intestino.El tratamiento de tratamiento de tratamiento de tratamiento.La colitis ulcerosa también se conoce como colitis ulcerosa.

Más Videos Relacionados

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.7K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.3K

Videos de Experimentos Relacionados

Last Updated: Feb 24, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.7K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.7K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.3K

Área de la Ciencia:

  • Gastroenterología y Gastroenterología.
  • Farmacoeconomía La farmacoeconomía es la economía de las drogas.
  • La Medicina Integral es una medicina integrada.

Sus antecedentes:

  • El tratamiento de la colitis ulcerosa activa (UC) a menudo implica terapias avanzadas.
  • La curcumina y QingDai (CurQD), un compuesto a base de hierbas, son prometedores para el manejo de la UC.
  • No existe un análisis previo de costo-efectividad para CurQD en el tratamiento de UC.

Objetivo del estudio:

  • Evaluar la rentabilidad de CurQD en comparación con las terapias avanzadas actuales para la UC moderada a grave.
  • Para analizar la relación costo-efectividad tanto para las cohortes de pacientes de UC naïve de terapia avanzada como para las experimentadas.

Principales métodos:

  • Un modelo de Markov simuló la progresión de los pacientes con UC durante 54 semanas.
  • Datos de eficacia sintetizados a partir de ensayos controlados aleatorios y estudios en el mundo real.
  • Datos de costos basados en el precio mayorista promedio de EE.UU.; se utilizó el umbral de $50,000/QALY.

Principales resultados:

  • CurQD demostró una relación costo-efectividad incremental (ICER) superior a $ 200,000 / QALY frente a las terapias avanzadas.
  • Las diferencias en el año de vida ajustado por calidad (QALY) fueron marginales, y oscilaron entre -0,1 y 0,07.
  • El análisis de sensibilidad confirmó la solidez de los hallazgos.

Conclusiones:

  • CurQD presenta una alternativa significativamente rentable a las terapias avanzadas de UC.
  • El costo reducido y la eficacia probada de CurQD ofrecen un beneficio convincente.
  • Esto incluye la rentabilidad frente a los biosimilares anti-TNF para la UC activa.